GlassScriptPhysician profile
Alexander James Cherry
NPI 1053796730
$1,824.01
in general payments reported to CMS, 2019-2025
19 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $39.50 · 2021: $89.07 · 2022: $231 · 2023: $233 · 2024: $548 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,256.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $611.04 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Alcon Vision LLC | $307.31 | 2022-2025 | Rocklatan, Argos, Clareon |
| Ivantis, INC | $205.72 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $120.44 | 2022-2025 | |
| Sight Sciences, INC. | $93.00 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| New World Medical,INC. | $69.32 | 2023-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Allergan, INC. | $68.26 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $60.54 | 2021-2024 | Acthar |
| Biotissue Holdings INC. | $50.93 | 2024 | |
| Mallinckrodt Enterprises LLC | $33.37 | 2019 | |
| Glaukos Corporation | $31.58 | 2025 | Istent Infinite, Idosetr |
| Dompe US, INC. | $26.97 | 2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $23.48 | 2024 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $23.11 | 2024 | Xdemvy |
| Genentech USA, INC. | $23.08 | 2025 | Vabysmo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.90 | 2019 | |
| Oyster Point Pharma, INC. | $20.00 | 2023 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $18.93 | 2025 | Syfovre |
| Bausch & Lomb Americas INC. | $16.03 | 2025 | Vyzulta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.